Impact of HIV kick-and-kill therapy on host epigenetic and transcriptional programs in PBMC, and viral rebound after cART interruption

Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals (NCT02616874). Out of 12 evaluable participants fo...

Descripción completa

Detalles Bibliográficos
Autores: Oriol-Tordera, Bruna, Esteve-Codina, Anna, Berdasco, María, Gonçalves, Elena, Esteller, Manel, Hanke, Tomá, Moltó, José, Clotet, Bonaventura, 1953-, Calle, María Luz, Combadiere, Behazine, Sànchez, Àlex (Sànchez Pla), Mothe, Beatriz, Ruiz-Riol, Marta, Brander, Christian
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/198070
Acceso en línea:https://hdl.handle.net/2445/198070
Access Level:acceso abierto
Palabra clave:VIH (Virus)
Epigenètica
HIV (Viruses)
Epigenetics
Descripción
Sumario:Background: BCN02 was a pilot kick-and-kill clinical trial that combined therapeutic vaccination (MVA.HIVconsv) with the latency reversing agent romidepsin (RMD) followed by a monitored antiretroviral pause (MAP) in 15 early-treated HIV+ individuals (NCT02616874). Out of 12 evaluable participants for an omics subanalysis, 8 participants showed early (pVL > 2000 copies/mL < 4 weeks) and 4 a more delayed viral rebound (pVL > 2000 copies/mL > 4 weeks) in MAP. Systems biology analyses identified epigenetic and molecular mechanisms associated with response to vaccination and RMD and viral rebound kinetics.

Similares en LA Referencia